237 related articles for article (PubMed ID: 33334316)
61. Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye.
Carrasco MA; Schlaen BA; Zárate JO
Int Ophthalmol; 2013 Oct; 33(5):557-60. PubMed ID: 23224363
[TBL] [Abstract][Full Text] [Related]
62. A paradoxical ocular effect of brimonidine.
Mushtaq B; Sardar J; Matthews TD
Am J Ophthalmol; 2003 Jan; 135(1):102-3. PubMed ID: 12504711
[TBL] [Abstract][Full Text] [Related]
63. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension.
Mundorf T; Noecker RJ; Earl M
Adv Ther; 2007; 24(2):302-9. PubMed ID: 17565920
[TBL] [Abstract][Full Text] [Related]
64. Safety and efficacy of brimonidine in children with glaucoma.
Enyedi LB; Freedman SF
J AAPOS; 2001 Oct; 5(5):281-4. PubMed ID: 11641636
[TBL] [Abstract][Full Text] [Related]
65. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
66. [Clinical efficacy of 0.2% brimonidine in patients with open-angle glaucoma or ocular hypertension].
Shi JM; Jiang YQ
Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):263-6. PubMed ID: 12575311
[TBL] [Abstract][Full Text] [Related]
67. Efficacy of brimonidine in preventing intraocular pressure spikes following phacoemulsification in glaucoma patients.
Kandarakis A; Soumplis V; Karampelas M; Panos C; Kyriakos N; Baxevanakis A; Karagiannis D
Eur J Ophthalmol; 2010; 20(6):994-9. PubMed ID: 20544673
[TBL] [Abstract][Full Text] [Related]
68. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
Adkins JC; Balfour JA
Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
[TBL] [Abstract][Full Text] [Related]
69. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
Walters TR
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
[TBL] [Abstract][Full Text] [Related]
70. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
[TBL] [Abstract][Full Text] [Related]
71. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
72. [The ocular hypotensive effect and safety of 0.2% brimonidine].
Yu M; Li Y; Ge J
Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
[TBL] [Abstract][Full Text] [Related]
73. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
74. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
Hommer A; Kapik B; Shams N;
Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
[TBL] [Abstract][Full Text] [Related]
75. Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine.
Chihara E; Dimitrova G; Chihara T
Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1257-1264. PubMed ID: 29520478
[TBL] [Abstract][Full Text] [Related]
76. Drugs, Inflammation, and the Eye.
Cunningham ET; London NJ; Moorthy R; Garg SJ; Zierhut M
Ocul Immunol Inflamm; 2016; 24(2):125-7. PubMed ID: 27074544
[No Abstract] [Full Text] [Related]
77. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
Javitt J; Goldberg I
J Glaucoma; 2000 Oct; 9(5):398-408. PubMed ID: 11039742
[TBL] [Abstract][Full Text] [Related]
78. A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004.
Feldman RM; Katz G; McMenemy M; Hubatsch DA; Realini T
Am J Ophthalmol; 2016 May; 165():188-97. PubMed ID: 26940161
[TBL] [Abstract][Full Text] [Related]
79. Brimonidine .2% as a replacement for beta blockers in geriatric patients with glaucoma.
Noecker RJ;
Adv Ther; 2002; 19(2):91-7. PubMed ID: 12069372
[TBL] [Abstract][Full Text] [Related]
80. Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up.
Yeh PH; Cheng YC; Shie SS; Lee YS; Shen SC; Chen HS; Wu WC; Su WW
Medicine (Baltimore); 2021 Jul; 100(29):e26724. PubMed ID: 34398046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
